These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27751671)

  • 1. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
    Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
    Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
    Nguyen HV; Bose S; Finkelstein E
    BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
    Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
    Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
    Ruggeri M; Bellasi A; Cipriani F; Molony D; Bell C; Russo D; Di Iorio B
    J Nephrol; 2015 Oct; 28(5):593-602. PubMed ID: 25027030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis.
    Grima DT; Dunn ES; Bernard LM; Mendelssohn DC
    Curr Med Res Opin; 2013 Feb; 29(2):109-15. PubMed ID: 23216385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic evaluation of sevelamer in patients new to dialysis.
    Taylor MJ; Elgazzar HA; Chaplin S; Goldsmith D; Molony DA
    Curr Med Res Opin; 2008 Feb; 24(2):601-8. PubMed ID: 18205996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients.
    Cho JH; Jang HM; Jung HY; Choi JY; Park SH; Kim CD; Yang CW; Jin DC; Kim YL
    Clin Ther; 2018 Jan; 40(1):123-134. PubMed ID: 28291581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
    Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
    Keith MS; Wilson RJ; Preston P; Copley JB
    Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):287-298. PubMed ID: 30664365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
    St Peter WL; Liu J; Weinhandl E; Fan Q
    Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
    St Peter WL; Fan Q; Weinhandl E; Liu J
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1954-61. PubMed ID: 19833904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders.
    Goh BL; Soraya A; Goh A; Ang KL
    Int J Nephrol; 2018; 2018():2138528. PubMed ID: 30327732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.